If CanSino's vaccine works, the collaboration could help ensure that Canadians have access to it. Local trial data could reassure Health Canada that the vaccine is safe, and local manufacturing could ensure some doses are at hand. Asked whether the collaboration would make it possible for Health Canada to consider data gathered in China, NRC said that in general, data can be shared with the regulator's approval. Shares of Hong Kong-listed CanSino rose on April 26 after the company said Health Canada had agreed to meet to discuss a clinical trial application. Separately on Tuesday, Canada promised C$600 million to replenish the GAVI vaccine alliance, to support routine vaccinations around the world.

Source: bd News24 May 12, 2020 18:11 UTC